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Hypertension is amajorandcorrectablecardiovascular risk factor. Thecorrectdiagnosisofhypertensionandpreciseassessment
ofcardiovascular riskareessential togiveproper treatment inpatientswithhypertension.Althoughechocardiography is the
second-linestudy in theevaluationofhypertensivepatients, it givesmanyclues suggestingbadprognosis associatedwith
hypertension, including increased left ventricular (LV)mass,decreasedLVsystolic function, impairedLVdiastolic function, and
increased left atrial sizeanddecreased function.Alongwithconventionalechocardiographicmethods, tissueDoppler imaging,
three-dimensionalechocardiography, andstrainechocardiographyarenewerechocardiographicmodalities in theevaluation
ofhypertensivepatients in thecurrentechocardiographic laboratories.Understandingconventional andnewer
echocardiographicparameters is important in thediagnosis andassessmentofcardiovascular risk inhypertensivepatients.
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Cardiovascular diseases are major leading health prob-
lems in the world [1], and hypertension is a major risk
factor for cardiovascular diseases and stroke which have
significantly higher morbidity and mortality [2].
Althoughtheechocardiographicexamination isusually rec-
ommended as a second-line study in the evaluation of hyper-
tensive patients, it is one of most commonly used imaging
modalityandhasgiven insights intopathophysiologyandclin-
ical implications in patients with hypertension. It can detect
anatomical and functional changes easily in a real-time, quick,
andreproduciblemanner.Echocardiography ismoresensitive
for the detection of asymptomatic organ damage that can be
usedasadeterminantofcardiovascular risk.So, it is important
in theclinicalmanagement inselectedhypertensivepatients.
In this review, we want to describe the role of echocar-
diography in the evaluation of hypertensive patients.Review
Recommendations of echocardiography in the current
hypertension guidelines
In the 2013 ESH/ESC Guidelines for the management of
arterial hypertension, echocardiography is the second-line* Correspondence: jaehpark@cnu.ac.kr
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creativecommons.org/publicdomain/zero/1.0/study based on medical history, physical examination, and
findings from routine laboratory tests [3]. The guidelines
recommended performing echocardiographic examination
in patients who are suspected with having left ventricular
hypertrophy (LVH), left atrial (LA) dilatation, or concomi-
tant heart diseases (class IIb: usefulness/efficacy is less well
established by evidence/opinion, level C: consensus of
opinion of the experts and/or small studies, retrospective
studies, and registries).
The 2014 Canadian Hypertension Education Program
(CHEP) guidelines recommended the echocardiographic
use in the selected patients [4]. Routine echocardiographic
study is not recommended in all patients with hypertension
(grade D: recommendations are based on expert opinion
alone). However, the echocardiographic examination for
the evaluation of LVH is useful in selected patients to define
the future cardiovascular risk (grade C: recommendations
are based on trials that have lower levels of internal validity
and/or precision, trials reporting invalidated surrogate out-
comes, or results from non-randomized observational stud-
ies). Echocardiographic evaluation of LV mass and systolic
and diastolic LV function is recommended in patients with
hypertension suspected to have LV dysfunction or coronary
artery disease (grade D). LV ejection fraction (LVEF) should
be assessed objectively by an echocardiogram or nuclear
imaging in patients with hypertension and evidence of heart
failure (grade D).article distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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mittee (JNC 8) did not mention about the use of echocar-
diography [5]. The previous guideline of JNC 7 discussed
about the echocardiographic examination to detect LVH
in the assessment of cardiovascular risk [6].
Appropriateness of echocardiography in hypertension
Because the echocardiography is the most common and
the first-line imaging study in many clinical scenarios,
appropriateness is an important issue in reducing the
cost of inappropriate use of echocardiography. The
American College of Cardiology Foundation published
the appropriate use criteria for echocardiography in co-
operation with the American Society of Echocardiog-
raphy and along with key specialty and subspecialty
societies [7]. They have analyzed many clinical scenarios
and categorized three groups according to the appropri-
ate use score: appropriate (median 7–9), uncertain (me-
dian 4–6), and inappropriate (median 1–3).
The use of echocardiography as an initial evaluation of
suspected hypertensive heart disease is appropriate (ap-
propriate use score 8). Also, echocardiography is appro-
priate in patients with prior test result that is concerning
for heart disease or structural abnormality (appropriate
use score 9). Initial evaluation of known or suspected
heart failure (HF), systolic or diastolic, based on symp-
toms, signs, or abnormal test results, is appropriate (ap-
propriate use score 9). Re-evaluation of known HF with
a change in clinical status or cardiac examination with-
out a clear precipitating change in medication or diet is
appropriate (appropriate use score 8).
However, routine evaluation of systemic hypertension
without symptoms or signs of hypertensive heart disease
is inappropriate (appropriate use score 3). Initial echo-
cardiographic evaluation of ventricular function with no
symptoms or signs of cardiovascular disease is inappro-
priate (appropriate use score 2). It is also inappropriate
for the evaluation of LV function with prior ventricular
function evaluation showing normal function in patients
in whom there has been no change in clinical status or
cardiac examination (appropriate use score 1). However,
re-evaluation of known hypertensive heart disease with-
out a change in clinical status or cardiac examination is
uncertain (appropriate use score 4). The usual recom-
mendations of echocardiographic examination in the
evaluation of arterial hypertension are summarized in
Table 1, and simplified algorithm of the echocardiog-
raphy is summarized in Figure 1.
Echocardiographic evaluations
Left ventricular mass and geometry
The evaluation of LVH with measuring mass and geom-
etry is the major role of echocardiography in hypertensive
patients. In the detection of LVH, echocardiographicassessment is more sensitive than electrocardiography
[8,9]. Echocardiography is a good diagnostic tool in the
determination of overall cardiovascular risk and helps in
the selection of appropriate antihypertensive therapy [9].
The calculation of LV mass is based on subtraction of
the LV cavity volume from the volume enclosed by the
LV epicardial surface. To measure proper LV mass, pre-
cise evaluation of thicknesses of the interventricular
septum and LV posterior wall in addition to the dimension
of the interventricular cavity is needed. The LV mass has
been measured using this equation that has been recom-
mended by the American Society of Echocardiography
(ASE) which is derived from two-dimensional linear LV
measurements [10];
Left ventricularmass gramð Þ
¼ 0:8 1:04
 LVIDdþ PWTdþ SWTdð Þ3−LVIDd3 þ 0:6
where LVIDd is the LV internal dimension at end dia-
stole, PWTd is the LV posterior wall thickness at end
diastole, and SWTd is interventricular septal wall thick-
ness at end diastole. Although this ASE-recommended
formula showed excellent correlation with necropsy study
(r = 0.90, p < 0.001) [11], even small errors in the measure-
ment are magnified and lead to big differences [10].
The relative wall thickness (RWT) is calculated by the
formula (2 × PWTd)/LVIDd [10]. RWT can categorize
the LVH as either concentric (RWT greater than 0.42) or
eccentric (RWT less than 0.42). With certain cutoff
values for LV mass have been widely accepted for the
presence of LVH (125 g/m2 for men and 110 g/m2 for
women), patients with hypertension can be classified
into four subgroups (Figure 2) [10,12]. LV geometric pat-
tern provides additional prognostic information in
hypertensive patients. Concentric hypertrophy is associ-
ated with increased cardiovascular events after adjust-
ment for other cardiovascular risk factors including LV
mass [13]. Also, concentric hypertrophy showed the
greatest mortality risk in patients suspected with coron-
ary artery disease [14].
Three-dimensional echocardiography has been intro-
duced to assess LV mass (Figure 3A) [15,16]. Because M-
mode and two-dimensional echocardiographic techniques
have many limitations, three-dimensional echocardiography
provides more precise measurements theoretically. Real-
time three-dimensional echocardiographic measurement of
LV mass showed an excellent correlation (r = 0.95, p <
0.001) with measurement by magnetic resonance imaging
[16]. Real-time three-dimensional measurement showed
better degree of agreement than M-mode or two-
dimensional calculation of LV mass. Also, inter- and
intraobserver variability were lower in the real-time three-
dimensional echocardiographic method. Because of these
Table 1 Clinical situations when the echocardiography is recommended in the evaluation and treatment of arterial
hypertension
Clinical situations Signs
Heart failure is suspected -Symptoms: exertional dyspnea, orthopnea, generalized edema, etc.
-Abnormal physical examination: cardiac murmurs, pretibial pitting edema, etc.
-Abnormal ECG results: left ventricular hypertrophy, left atrial enlargement, left bundle branch block, pathologic Q
waves, poor R progression, atrial fibrillation etc.
-Abnormal chest X-ray findings: cardiomegaly, pulmonary edema, pleural effusion, etc.
Structural heart disease is
suspected
-Symptoms: exertional dyspnea, orthopnea, etc.
-Abnormal physical examination: cardiac murmurs, pretibial pitting edema, etc.
-Abnormal ECG results: left ventricular hypertrophy, right ventricular hypertrophy, left atrial enlargement, right atrial
enlargement, etc.
-Abnormal chest X-ray findings: cardiomegaly, pulmonary edema, pleural effusion, etc.
Ischemic heart disease is
suspected
-Symptoms: typical chest pain, exertional dyspnea, etc.
-Abnormal ECG results: significant ST changes, pathologic Q wave, etc.
Refining cardiovascular risk
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ography, three-dimensional echocardiographic measure-
ment can be a technique of choice in the studies of the
regression of LVH with antihypertensive medications.
Left ventricular systolic function
Rapid and reliable assessment of LV systolic function is
another advantage of the echocardiography. Although cor-
onary artery disease is the most common cause of LV
systolic dysfunction, arterial hypertension is a possible
cause of functional impairment of the LV. Echocardiog-
raphy can give information about the possibility of coron-
ary artery disease in addition to calculation of LV function.
Several echocardiographic indices have been introduced
to estimate LV systolic function. Among them, LVEF is the
most used and the most practical systolic index that has
been used as a prognostic factor in various cardiovascularFigure 1 Diagnostic flowchart in the evaluation of hypertension.
Usually, the echocardiography is a second-line test. Bold solid lines
refer to routine recommendation. Solid lines refer to tests that ‘can
be recommended’.diseases [16,17]. It can be calculated from the ratio
between the volume ejected during systole over the end-
diastolic volume of the LV. Echocardiographic measure-
ment of ejection fraction is usually done using modified
Simpson’s method (Figure 4) [10,18]. A normal LVEF is
more than 55% in adults [10].
Three-dimensional echocardiographic measurements of
LV volumes have been available with technical improve-
ment (Figure 3B) [19-21]. Three-dimensional measure-
ment does not require the assumption that the LV is a
prolate ellipse, and it can measure LV volumes as it is. So,
three-dimensional echocardiographic measurement has
advantages over the calculation of LV volumes in patients
with regional wall motion abnormalities or LV aneurysms.Figure 2 Classification of hypertensive patients according to
the presence of left ventricular hypertrophy and the relative
wall thickness.
Figure 3 Examples of calculation of left ventricular mass (A) and volumes (B) by three-dimensional echocardiography.
Figure 4 Two-dimensional calculations for volume calculations using biplane methods of disks (modified Simpson’s method) in apical
4 chamber (A and B) and apical 2 chamber views (C and D). Ejection fraction can be measured from the division of the stroke volume
(subtraction of end-systolic volume from end-diastolic volume) by end-diastolic volume.
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been shown high degree of agreement with the measure-
ments by cardiac magnetic resonance imaging [22-24].
Moreover, these studies demonstrated significant increases
in reproducibility over conventional two-dimensional echo-
cardiographic measurements.
Because impairment of LV long-axis function occurs
at the early stages in many cardiac diseases, its assess-
ment provides a very useful index in the evaluation of
hypertensive patients [25]. The LV longitudinal function
can be assessed with atrioventricular plane displacement
that was abnormal in hypertensive patients without overt
systolic dysfunction [26].
Tissue Doppler imaging is the new echocardiographic
modality to measure mitral annular movement. Mitral
annular velocity was decreased in hypertensive patients
with normal ejection fraction [27], and it can be used to
detect subclinical LV systolic dysfunction [28]. Measure-
ments of myocardial function by strain echocardiog-
raphy are newer indices that have advantages over other
conventional echocardiographic measurements like LVEF.
Strain can measure global and regional myocardial func-
tion, objectively. Two-dimensional speckle-tracking echo-
cardiography analyzes myocardial deformation by tracking
of natural acoustic markers that are generated from the
interactions between ultrasound and myocardium. These
natural acoustic markers are referred to as speckles
[29,30]. Although there are several echocardiographic
algorithms tracking the speckles, they are able to get
angle-independent and multi-directional (longitudinal, ra-
dial, and circumferential) strain values [31]. Moreover,
inter- and intraobserver variability of two-dimensional
strain echocardiography are better than tissue Doppler
values [32].
Myocardial strain can detect subclinical organ damage
earlier than other conventional echocardiographic param-
eters. Kang et al. [33] reported longitudinal strain was de-
creased in hypertensive patients with normal LV systolic
function, and it was correlated with serum level of tissue
inhibitor of matrix metalloproteinase-1 level, a marker of
myocardial fibrosis.
Three-dimensional strain echocardiography has been
developed by technological advancement, and it can track
the motion of myocardial speckles stereoscopically [34].
Analysis of the whole LV from a single volume data is the
main advantage of three-dimensional strain echocardiog-
raphy (Figure 5). It can measure longitudinal, circumferen-
tial, radial, and area strain and can also reduce the time
duration required for analysis [35]. Circumferential strain
by three-dimensional echocardiography showed better cor-
relation with LVEF than with global longitudinal strain and
radial strain, especially in patients with preserved LV func-
tion [36]. Recent studies reported that global area strain is
the most reliable surrogate of LVEF [37,38]. Global areastrain by three-dimensional strain echocardiography was
precociously decreased in hypertensive patients with nor-
mal LV systolic function [39]. Three-dimensional echo-
cardiographic strain analysis also can measure regional
myocardial function.
Left ventricular diastolic function
Diastole is a period to fill the LV, and normal diastolic
function is required to fill the cardiac chambers without
abnormally elevated pressure [40]. The diastole includes
four sub-phases: isovolumetric relaxation, early rapid ven-
tricular filling, diastasis, and atrial contraction. Diastole is
not a passive process, and it starts after LV contraction
[41]. The ventricular myocardium is compressed and
twisted during LV systole. The compressed and twisted
myocardium was relaxed and unloads the energy required
during diastole. Intra-ventricular pressure drops rapidly
during the first isovolumetric relaxation period. This re-
laxation makes a pressure difference between the LA and
ventricle that forced the rapid blood flow through the mi-
tral valve and fills the LV rapidly. During diastasis, blood
flow continues through the mitral valve. The atrial con-
traction is the last phase of the diastole, and blood is
pumped by the muscular contraction of the atrium.
Although LV diastolic dysfunction is associated with in-
creased mortality in middle-aged and elderly adults [42],
the estimation of LV diastolic function is more difficult
than the measurement of systolic function [43]. A com-
prehensive assessment of LV diastolic function should es-
timate LV filling pressure.
Echocardiography is a useful imaging tool to measure
LV diastolic function. Several echocardiographic mo-
dalities can be used to estimate LV filling pressure. In-
creased LA size and volume is one of indicator of
increased LV filling pressure [44,45]. Enlarged LA
diameter was found more than 20% of hypertensive pa-
tients in a large-scale study including a total of 2,500
uncomplicated essential hypertensives [46]. Enlarged
LA can present long-standing elevated LV filling pres-
sure, and increased LA size and volume were associ-
ated with poor long-term mortality and morbidity
[47,48].
Mitral inflow pattern by pulsed-wave Doppler tech-
nique is another maker of diastolic function (Figure 6A).
Isovolumic relaxation time, ratio of E and A velocities,
deceleration time of E velocity, and duration of A wave
can be used to assess diastolic dysfunction [49]. However,
these velocities can be influenced by multiple factors in-
cluding age, heart rate and rhythm, cardiac output, mitral
annular size, and LA function [49].
Mitral annular velocity can be assessed by pulsed-wave
Doppler of mitral annulus from tissue Doppler imaging
(Figure 6B). Because e’ velocity measured by tissue Dop-
pler imaging is inversely proportionate to the relaxation
Figure 5 Multiplanar reconstruction images are obtained automatically from single volumetric echocardiographic data. Global longitudinal
(A), circumferential (B), radial (C), and area strains (D) can be measured as well as regional segmental values at one analysis.
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is proportionate to the ratio between LA pressure and
tau, the ratio E/e’ can be a good indicator of LA pressure
[50-52], and it is generally the most feasible marker for
estimation of LA filling pressure. Several validation
studies have showed good correlation of this ratio with
LA filling pressure, and the prediction of normal filling
pressure is most reliable when the ratio is <8. When the
ratio is >15, it is an indicator of increased LA filling
pressure [49,52].
However, the E/e’ ratio has pitfalls in the assessment of
LA filling pressure [53]. The E/e’ ratio had a poor correl-
ation with LA pressures in patients with advanced systolic
heart failure [54]. Situations where the use of E/e’ may be
unreliable in tachycardia with fusion of mitral E and A vel-
ocities, significant valvular heart disease (significant mitral
regurgitation, significant mitral stenosis, and aortic regur-
gitation), and presence of left bundle branch block [53].
Diastolic stress echocardiography using exercise stress
can detect hemodynamic consequences of exercise-inducedincrease in diastolic filling pressure noninvasively [55]. It
can detect subclinical diastolic dysfunction and can be valu-
able in patients with unexplained dyspnea [55].
Left atrial size and function
LA enlargement is commonly associated with systemic ar-
terial hypertension in patients without significant valvular
heart disease, and it is associated with overweight, LVH,
and metabolic syndrome [46]. LA size can be calculated
with parasternal long-axis view at end systole along its
greatest dimension, trying to avoid foreshortening it.
Normal LA diameter is 2.7 ~ 3.8 cm for female and 3.0 ~
4.0 cm for male [10].
LA volume can be assessed by two-dimensional echocar-
diography (Figure 7). Normal LA volume is lower than
28 ml/m2 [10], and enlarged LA is one of the poor prognos-
tic markers. Increased LA size and volume can reflect the
diastolic dysfunction in hypertensive patients and can be
used as one of indicators of cardiovascular morbidity and
mortality [45]. Volume more than 34 ml/m2 is associated
Figure 6 Left ventricular diastolic function can be assessed with mitral inflow velocity and mitral annular velocity. Mitral inflow velocities
obtained by pulsed-wave Doppler technique (A) and their schematic diagram. Peak mitral inflow velocity during early diastole (E wave), peak mitral
inflow velocity at atrial contraction (A wave), mitral deceleration time (DT), duration of A wave (Adur). Mitral annular velocities obtained by tissue
Doppler echocardiography with e’ velocity as the early diastolic velocity and a’ velocity as the late diastolic velocity (B).
Figure 7 Measurement of left atrial volume from area-length method using apical 4 chamber (A1) and apical 2 chamber (A2) views at
ventricular end systole. L* is the shortest of either the apical 4 chamber or apical 2 chamber length.
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rillation, and ischemic stroke [56,57]. Because the LA does
not show rapid reverse remodeling with treatment, its size
or volume is an inadequate marker of therapeutic response.
LA function is important in the regulation of LV filling
by reservoir, conduit, and booster pump functions [58].
LA reservoir and conduit functions are essential during
the early diastolic phase, and booster pump function is
needed in active filling of the LV during the late diastolic
phase. The echocardiographic assessment of LA function
is relatively difficult due to its anatomical shape [59].
Tissue Doppler imaging has been introduced to measure
LA booster function. The positive wave during systole
(SRs) reflects the reservoir function, the negative wave
during early diastole (SRe) indicates the conduit func-
tion, and the negative wave during late diastole (SRa)
represents the booster pump function [60,61]. LA strain
and strain rate can detect subclinical atrial dysfunction
in patients with hypertension [61]. However, strain and
strain rate assessed by tissue Doppler imaging have limi-
tation about angle dependency, and the deformation
characteristics of the LA in hypertensive patients are still
controversial [62].
Two-dimensional speckle-tracking echocardiography has
been used in the assessment of LA function in a noninva-
sive, simple, and reproducible manner [63]. Hypertensive
patients with decreased LA function assessed by speckle-
tracking echocardiography have poor prognosis [64,65].
Also, strain and strain rate from two-dimensional speckle-
tracking echocardiography may reflect decreased LA con-
duit function and increased booster pump function in
hypertensive patients with LVH [63].
Analysis of LA appendage can give indirect informa-
tion about LA function, and impaired LA appendageal
function in patients with non-dipper compared to dipper
hypertensive patients [66]. Although the strain measure-
ment of LA is not recommended in routine clinical
practices, it can be a good indicator of LA function.
Three-dimensional echocardiography has been intro-
duced in the measurement of LA size and volume, and it
gives many advantages over two-dimensional echocardiog-
raphy [67]. Real-time three-dimensional echocardiography
can provide a reproducible assessment and passive LA
function by volumetric cyclic changes [68]. Its measure-
ment of LA volume showed well correlation with LA vol-
ume by multi-detector computerized tomography [69]. It
may be superior to the two-dimensional echocardiography
because of its higher sensitivity to volume changes [68].
Other echocardiographic findings in hypertensive
patients
Secondary pulmonary hypertension can be resulted
from increased LA pressure transmitted to pulmonary
circulation. Also, HF with preserved ejection fractionis a common cause of pulmonary hypertension [70]. Echo-
cardiography can estimate pulmonary arterial pressure with
tricuspid regurgitation velocity or right ventricular outflow
track flow profile [71]. Pulmonary arterial systolic pressure
can be assessed by adding pressure gradient through right
heart chambers (calculated with the Bernoulli equation) to
right atrial pressure [72].
PASP ¼ RVSP ¼ RAPþ 4 TRVmax2
Where PASP is the pulmonary artery systolic pressure,
RVSP is the right ventricular systolic pressure, TR Vmax
is the maximal tricuspid regurgitant velocity, and RAP is
the right atrial pressure.
Right ventricular outflow tract acceleration time is the
time from the beginning of the right ventricular ejection
until the maximum of the systolic velocity [73]. This
acceleration time is about 140 ms in normal people, and
it shortens in patients with pulmonary hypertension
(about 80 ms).
Because systemic arterial hypertension is also a risk
factor of atherosclerosis, atherosclerotic heart diseases
can be seen during echocardiographic examination. Is-
chemic heart disease, dilatation of ascending aorta, and
aortic valve sclerosis or stenosis can be found. Presence
of regional wall motion abnormalities or ventricular
aneurysm is associated with ischemic coronary artery dis-
eases. Stress echocardiography with using exercise proto-
col or dobutamine stress can detect ischemic heart
diseases more sensitively. Dilatation of ascending aorta is
associated with increased arterial stiffness and LV mass,
and its reported incidence was 17% in hypertensive pa-
tients [74]. Calcific aortic valve diseases are usual manifes-
tations of atherosclerosis. The presence of aortic valve
sclerosis is associated with poor clinical outcomes [75,76].
Conclusion
Because echocardiography can detect cardiac morphologic
and hemodynamic change caused by systemic arterial
hypertension, echocardiography is a powerful tool for the
evaluation of target organ damage, which is essential for
the evaluation of cardiovascular risk. Although echocardi-
ography is not an essential first-line imaging study, echo-
cardiography is an excellent tool for the assessment of
future cardiovascular risks. Because of its non-invasiveness
and easy accessibility, it is also a widely and most com-
monly used imaging modality in the cardiology practice.
However, conventional echocardiography has many pitfalls
in the interpretation of several echocardiographic parame-
ters. To overcome this limitation, physicians should be
aware of the pitfalls of conventional echocardiographic pa-
rameters. Second, doctors should analyze and interpret
echocardiographic findings in conjunction with other find-
ings from physical examination and routine examinations.
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learn other newer echocardiographc modalities. Aside
from conventional echocardiographic modalities, newer
echocardiographic methods including tissue Doppler
imaging, strain echocardiography, or three-dimensional
echocardiography also have been introduced to evaluate
hypertensive patients providing valuable information
about the extent of cardiac damages thus helping us to
give better treatment.
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